1887

Abstract

Almost 30 years after its initial discovery, infection with the human immunodeficiency virus-1 (HIV-1) remains incurable and the virus persists due to reservoirs of latently infected CD4 memory T-cells and sanctuary sites within the infected individual where drug penetration is poor. Reactivating latent viruses has been a key strategy to completely eliminate the virus from the host, but many difficulties and unanswered questions remain. In this review, the latest developments in HIV-persistence and latency research are presented.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.049296-0
2013-05-01
2022-01-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/5/917.html?itemId=/content/journal/jgv/10.1099/vir.0.049296-0&mimeType=html&fmt=ahah

References

  1. Ackley C. D., Yamamoto J. K., Levy N., Pedersen N. C., Cooper M. D. 1990; Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 64:5652–5655[PubMed]
    [Google Scholar]
  2. Alexaki A., Wigdahl B. 2008; HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog 4:e1000215 [View Article][PubMed]
    [Google Scholar]
  3. Allers K., Hütter G., Hofmann J., Loddenkemper C., Rieger K., Thiel E., Schneider T. 2011; Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117:2791–2799 [View Article][PubMed]
    [Google Scholar]
  4. Anderson J., Li M.-J., Palmer B., Remling L., Li S., Yam P., Yee J.-K., Rossi J., Zaia J., Akkina R. 2007; Safety and efficacy of a lentiviral vector containing three anti-HIV genes–CCR5 ribozyme, tat-rev siRNA, and TAR decoy–in SCID-hu mouse-derived T cells. Mol Ther 15:1182–1188[PubMed] [CrossRef]
    [Google Scholar]
  5. Archin N. M., Espeseth A., Parker D., Cheema M., Hazuda D., Margolis D. M. 2009; Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25:207–212 [View Article][PubMed]
    [Google Scholar]
  6. Archin N. M., Liberty A. L., Kashuba A. D., Choudhary S. K., Kuruc J. D., Crooks A. M., Parker D. C., Anderson E. M., Kearney M. F. other authors 2012; Administration of Vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482–485 [View Article][PubMed]
    [Google Scholar]
  7. Assogba B. D., Leavell S., Porter K., Burkhard M. J. 2007; Mucosal administration of low-dose cell-associated feline immunodeficiency virus promotes viral latency. J Infect Dis 195:1184–1188 [View Article][PubMed]
    [Google Scholar]
  8. Bai J., Gorantla S., Banda N., Cagnon L., Rossi J., Akkina R. 2000; Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo . Mol Ther 1:244–254 [View Article][PubMed]
    [Google Scholar]
  9. Bailey J. R., Sedaghat A. R., Kieffer T., Brennan T., Lee P. K., Wind-Rotolo M., Haggerty C. M., Kamireddi A. R., Liu Y. other authors 2006; Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80:6441–6457 [View Article][PubMed]
    [Google Scholar]
  10. Baldauf H. M., Pan X., Erikson E., Schmidt S., Daddacha W., Burggraf M., Schenkova K., Ambiel I., Wabnitz G. other authors 2012; SAMHD1 restricts HIV-1 infection in resting CD4+ T cells. Nat Med 18:1682–1689 [View Article][PubMed]
    [Google Scholar]
  11. Banerjee C., Archin N., Michaels D., Belkina A. C., Denis G. V., Bradner J., Sebastiani P., Margolis D. M., Montano M. 2012; BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92:1147–1154 [View Article][PubMed]
    [Google Scholar]
  12. Barlough J. E., Ackley C. D., George J. W., Levy N., Acevedo R., Moore P. F., Rideout B. A., Cooper M. D., Pedersen N. C. 1991; Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J Acquir Immune Defic Syndr 4:219–227[PubMed]
    [Google Scholar]
  13. Beatty J. A., Willett B. J., Gault E. A., Jarrett O. 1996; A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J Virol 70:6199–6206[PubMed]
    [Google Scholar]
  14. Bebenek K., Abbotts J., Wilson S. H., Kunkel T. A. 1993; Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J Biol Chem 268:10324–10334[PubMed]
    [Google Scholar]
  15. Benkirane M., Chun R. F., Xiao H., Ogryzko V. V., Howard B. H., Nakatani Y., Jeang K. T. 1998; Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 273:24898–24905 [View Article][PubMed]
    [Google Scholar]
  16. Berard M., Tough D. F. 2002; Qualitative differences between naïve and memory T cells. Immunology 106:127–138 [View Article][PubMed]
    [Google Scholar]
  17. Best B. M., Letendre S. L., Koopmans P., Rossi S. S., Clifford D. B., Collier A. C., Gelman B. B., Marra C. M., McArthur J. C. other authors 2012; Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 59:376–381 [View Article][PubMed]
    [Google Scholar]
  18. Biancotto A., Grivel J.-C., Gondois-Rey F., Bettendroffer L., Vigne R., Brown S., Margolis L. B., Hirsch I. 2004; Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78:10507–10515 [View Article][PubMed]
    [Google Scholar]
  19. Blazkova J., Trejbalova K., Gondois-Rey F., Halfon P., Philibert P., Guiguen A., Verdin E., Olive D., Van Lint C. other authors 2009; CpG methylation controls reactivation of HIV from latency. PLoS Pathog 5:e1000554 [View Article][PubMed]
    [Google Scholar]
  20. Bleul C. C., Wu L. J., Hoxie J. A., Springer T. A., Mackay C. R. 1997; The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 94:1925–1930 [View Article][PubMed]
    [Google Scholar]
  21. Boberg A., Bråve A., Johansson S., Wahren B., Hinkula J., Rollman E. 2008; Murine models for HIV vaccination and challenge. Expert Rev Vaccines 7:117–130 [View Article][PubMed]
    [Google Scholar]
  22. Bosque A., Planelles V. 2009; Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58–65 [View Article][PubMed]
    [Google Scholar]
  23. Bosque A., Famiglietti M., Weyrich A. S., Goulston C., Planelles V. 2011; Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog 7:e1002288 [View Article][PubMed]
    [Google Scholar]
  24. Brenchley J. M., Paiardini M. 2011; Immunodeficiency lentiviral infections in natural and non-natural hosts. Blood 118:847–854 [View Article][PubMed]
    [Google Scholar]
  25. Brenchley J. M., Schacker T. W., Ruff L. E., Price D. A., Taylor J. H., Beilman G. J., Nguyen P. L., Khoruts A., Larson M. other authors 2004a; CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749–759 [View Article][PubMed]
    [Google Scholar]
  26. Brenchley J. M., Hill B. J., Ambrozak D. R., Price D. A., Guenaga F. J., Casazza J. P., Kuruppu J., Yazdani J., Migueles S. A. other authors 2004b; T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 78:1160–1168 [View Article][PubMed]
    [Google Scholar]
  27. Brennan T. P., Woods J. O., Sedaghat A. R., Siliciano J. D., Siliciano R. F., Wilke C. O. 2009; Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 83:8470–8481 [View Article][PubMed]
    [Google Scholar]
  28. Brooks D. G., Kitchen S. G., Kitchen C. M. R., Scripture-Adams D. D., Zack J. A. 2001; Generation of HIV latency during thymopoiesis. Nat Med 7:459–464 [View Article][PubMed]
    [Google Scholar]
  29. Bukrinsky M. I., Stanwick T. L., Dempsey M. P., Stevenson M. 1991; Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423–427 [View Article][PubMed]
    [Google Scholar]
  30. Burke B., Brown H. J., Marsden M. D., Bristol G., Vatakis D. N., Zack J. A. 2007; Primary cell model for activation-inducible human immunodeficiency virus. J Virol 81:7424–7434 [View Article][PubMed]
    [Google Scholar]
  31. Burnett J. C., Rossi J. J. 2012; RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60–71 [View Article][PubMed]
    [Google Scholar]
  32. Burnett J. C., Lim K. I., Calafi A., Rossi J. J., Schaffer D. V., Arkin A. P. 2010; Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 84:5958–5974 [View Article][PubMed]
    [Google Scholar]
  33. Buzón M. J., Massanella M., Llibre J. M., Esteve A., Dahl V., Puertas M. C., Gatell J. M., Domingo P., Paredes R. other authors 2010; HIV-1 replication and immune dynamics are affected by Raltegravir intensification of HAART-suppressed subjects. Nat Med 16:460–465 [View Article][PubMed]
    [Google Scholar]
  34. Cabrita G. J. M., Ferreira B. S., da Silva C. L., Gonçalves R., Almeida-Porada G., Cabral J. M. S. 2003; Hematopoietic stem cells: from the bone to the bioreactor. Trends Biotechnol 21:233–240 [View Article][PubMed]
    [Google Scholar]
  35. Canestri A., Lescure F.-X., Jaureguiberry S., Moulignier A., Amiel C., Marcelin A. G., Peytavin G., Tubiana R., Pialoux G., Katlama C. 2010; Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 50:773–778 [View Article][PubMed]
    [Google Scholar]
  36. Carter C. C., Onafuwa-Nuga A., McNamara L. A., Riddell J. IV, Bixby D., Savona M. R., Collins K. L. 2010; HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16:446–451 [View Article][PubMed]
    [Google Scholar]
  37. Carter C. C., McNamara L. A., Onafuwa-Nuga A., Shackleton M., Riddell J. IV, Bixby D., Savona M. R., Morrison S. J., Collins K. L. 2011; HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9:223–234 [View Article][PubMed]
    [Google Scholar]
  38. Chahroudi A., Bosinger S. E., Vanderford T. H., Paiardini M., Silvestri G. 2012; Natural SIV hosts: showing AIDS the door. Science 335:1188–1193 [View Article][PubMed]
    [Google Scholar]
  39. Chan C. N., McMonagle E. L., Hosie M. J., Willett B. J. 2013; Prostratin exhibits both replication enhancing and inhibiting effects on FIV infection of feline CD4+ T-cells. Virus Res 171:121–128 [View Article][PubMed]
    [Google Scholar]
  40. Chen L. F., Mu Y., Greene W. C. 2002; Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 21:6539–6548 [View Article][PubMed]
    [Google Scholar]
  41. Chiang K., Rice A. P. 2012; MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses 4:1390–1409 [View Article][PubMed]
    [Google Scholar]
  42. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G. other authors 1996; The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135–1148 [View Article][PubMed]
    [Google Scholar]
  43. Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F. A., Yassine-Diab B., Boucher G., Boulassel M.-R., Ghattas G. other authors 2009; HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893–900 [View Article][PubMed]
    [Google Scholar]
  44. Choudhary S. K., Rezk N. L., Ince W. L., Cheema M., Zhang L., Su L., Swanstrom R., Kashuba A. D., Margolis D. M. 2009; Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2–/–γc–/– mouse. J Virol 83:8254–8258 [View Article][PubMed]
    [Google Scholar]
  45. Choudhary S. K., Archin N. M., Cheema M., Dahl N. P., Garcia J. V., Margolis D. M. 2012; Latent HIV-1 infection of resting CD4+ T cells in the humanized Rag2−/− γc−/− mouse. J Virol 86:114–120 [View Article][PubMed]
    [Google Scholar]
  46. Chun T. W., Finzi D., Margolick J., Chadwick K., Schwartz D., Siliciano R. F. 1995; In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1:1284–1290 [View Article][PubMed]
    [Google Scholar]
  47. Chun T. W., Carruth L., Finzi D., Shen X., DiGiuseppe J. A., Taylor H., Hermankova M., Chadwick K., Margolick J. other authors 1997; Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183–188 [View Article][PubMed]
    [Google Scholar]
  48. Chun T. W., Engel D., Mizell S. B., Ehler L. A., Fauci A. S. 1998; Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 188:83–91 [View Article][PubMed]
    [Google Scholar]
  49. Chun T. W., Davey R. T. Jr, Engel D., Lane H. C., Fauci A. S. 1999; Re-emergence of HIV after stopping therapy. Nature 401:874–875 [View Article][PubMed]
    [Google Scholar]
  50. Chun T. W., Nickle D. C., Justement J. S., Large D., Semerjian A., Curlin M. E., O’Shea M. A., Hallahan C. W., Daucher M. other authors 2005; HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115:3250–3255 [View Article][PubMed]
    [Google Scholar]
  51. Chun T.-W., Nickle D. C., Justement J. S., Meyers J. H., Roby G., Hallahan C. W., Kottilil S., Moir S., Mican J. M. other authors 2008; Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197:714–720 [View Article][PubMed]
    [Google Scholar]
  52. Churchill M. J., Gorry P. R., Cowley D., Lal L., Sonza S., Purcell D. F. J., Thompson K. A., Gabuzda D., McArthur J. C. other authors 2006; Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 12:146–152 [View Article][PubMed]
    [Google Scholar]
  53. Cicala C., Arthos J., Censoplano N., Cruz C., Chung E., Martinelli E., Lempicki R. A., Natarajan V., VanRyk D. other authors 2006; HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. Virology 345:105–114 [View Article][PubMed]
    [Google Scholar]
  54. Cillo A., Krishnan A., Mitsuyasu R., McMahon D., Li S., Rossi J., Zaia J., Mellors J. W. 2012; Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for AIDS-related lymphoma. In CROI Seattle, USA:
    [Google Scholar]
  55. Coffer P. J., Burgering B. M. 2004; Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 4:889–899 [View Article][PubMed]
    [Google Scholar]
  56. Coiras M., López-Huertas M. R., Pérez-Olmeda M., Alcamí J. 2009; Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 7:798–812 [View Article][PubMed]
    [Google Scholar]
  57. Coleman C. M., Wu L. 2009; HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6:51 [View Article][PubMed]
    [Google Scholar]
  58. Colin L., Van Lint C. 2009; Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111 [View Article][PubMed]
    [Google Scholar]
  59. Connor R. I., Sheridan K. E., Ceradini D., Choe S., Landau N. R. 1997; Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med 185:621–628 [View Article][PubMed]
    [Google Scholar]
  60. Contreras X., Schweneker M., Chen C.-S., McCune J. M., Deeks S. G., Martin J., Peterlin B. M. 2009; Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284:6782–6789 [View Article][PubMed]
    [Google Scholar]
  61. Coull J. J., Romerio F., Sun J. M., Volker J. L., Galvin K. M., Davie J. R., Shi Y., Hansen U., Margolis D. M. 2000; The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74:6790–6799 [View Article][PubMed]
    [Google Scholar]
  62. d’Arminio A., Sabin C. A., Phillips A. N., Reiss P., Weber R., Kirk O., El-Sadr W., De Wit S., Mateu S. other authors 2004; Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18:1811–1817 [View Article][PubMed]
    [Google Scholar]
  63. Dalgleish A. G., Beverley P. C., Clapham P. R., Crawford D. H., Greaves M. F., Weiss R. A. 1984; The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763–767 [View Article][PubMed]
    [Google Scholar]
  64. Davey R. T. Jr, Bhat N., Yoder C., Chun T. W., Metcalf J. A., Dewar R., Natarajan V., Lempicki R. A., Adelsberger J. W. other authors 1999; HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96:15109–15114 [View Article][PubMed]
    [Google Scholar]
  65. Davis B. R., Schwartz D. H., Marx J. C., Johnson C. E., Berry J. M., Lyding J., Merigan T. C., Zander A. 1991; Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol 65:1985–1990[PubMed]
    [Google Scholar]
  66. Dean M., Carrington M., Winkler C., Huttley G. A., Smith M. W., Allikmets R., Goedert J. J., Buchbinder S. P., Vittinghoff E. other authors 1996; Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856–1862 [View Article][PubMed]
    [Google Scholar]
  67. Deeks S. G. 2011; HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141–155 [View Article][PubMed]
    [Google Scholar]
  68. Deeks S. G., Autran B., Berkhout B., Benkirane M., Cairns S., Chomont N., Chun T. W., Churchill M., Di Mascio M. other authors 2012; Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12:607–614 [View Article][PubMed]
    [Google Scholar]
  69. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R. E. other authors 1996; Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661–666 [View Article][PubMed]
    [Google Scholar]
  70. Descours B., Cribier A., Chable-Bessia C., Ayinde D., Rice G., Crow Y., Yatim A., Schwartz O., Laguette N., Benkirane M. 2012; SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells. Retrovirology 9:87 [View Article][PubMed]
    [Google Scholar]
  71. Di Mascio M., Srinivasula S., Bhattacharjee A., Cheng L., Martiniova L., Herscovitch P., Lertora J., Kiesewetter D. 2009; Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob Agents Chemother 53:4086–4095 [View Article][PubMed]
    [Google Scholar]
  72. Dinoso J. B., Rabi S. A., Blankson J. N., Gama L., Mankowski J. L., Siliciano R. F., Zink M. C., Clements J. E. 2009a; A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 83:9247–9257 [View Article][PubMed]
    [Google Scholar]
  73. Dinoso J. B., Kim S. Y., Wiegand A. M., Palmer S. E., Gange S. J., Cranmer L., O’Shea A., Callender M., Spivak A. other authors 2009b; Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106:9403–9408 [View Article][PubMed]
    [Google Scholar]
  74. Douek D. C., Roederer M., Koup R. A. 2009; Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60:471–484 [View Article][PubMed]
    [Google Scholar]
  75. Durand C. M., Ghiaur G., Siliciano J. D., Rabi S. A., Eisele E. E., Salgado M., Shan L., Lai J. F., Zhang H. other authors 2012; HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis 205:1014–1018 [View Article][PubMed]
    [Google Scholar]
  76. Egberink H. F., Keldermans C. E., Koolen M. J., Horzinek M. C. 1992; Humoral immune response to feline immunodeficiency virus in cats with experimentally induced and naturally acquired infections. Am J Vet Res 53:1133–1138[PubMed]
    [Google Scholar]
  77. Eichbaum Q. 2011; PD-1 signaling in HIV and chronic viral infection–potential for therapeutic intervention?. Curr Med Chem 18:3971–3980 [View Article][PubMed]
    [Google Scholar]
  78. Eisele E., Siliciano R. F. 2012; Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37:377–388 [View Article][PubMed]
    [Google Scholar]
  79. Else L. J., Taylor S., Back D. J., Khoo S. H. 2011; Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 16:1149–1167 [View Article][PubMed]
    [Google Scholar]
  80. Feng Y., Broder C. C., Kennedy P. E., Berger E. A. 1996; HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872–877 [View Article][PubMed]
    [Google Scholar]
  81. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W. B., Fedorov O., Morse E. M., Keates T., Hickman T. T. other authors 2010; Selective inhibition of BET bromodomains. Nature 468:1067–1073 [View Article][PubMed]
    [Google Scholar]
  82. Finzi D., Hermankova M., Pierson T., Carruth L. M., Buck C., Chaisson R. E., Quinn T. C., Chadwick K., Margolick J. other authors 1997; Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295–1300 [View Article][PubMed]
    [Google Scholar]
  83. Flynn J. N., Dunham S., Mueller A., Cannon C., Jarrett O. 2002; Involvement of cytolytic and non-cytolytic T cells in the control of feline immunodeficiency virus infection. Vet Immunol Immunopathol 85:159–170 [View Article][PubMed]
    [Google Scholar]
  84. Folks T. M., Justement J., Kinter A., Dinarello C. A., Fauci A. S. 1987; Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800–802 [View Article][PubMed]
    [Google Scholar]
  85. Folks T. M., Kessler S. W., Orenstein J. M., Justement J. S., Jaffe E. S., Fauci A. S. 1988; Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 242:919–922 [View Article][PubMed]
    [Google Scholar]
  86. Folks T. M., Clouse K. A., Justement J., Rabson A., Duh E., Kehrl J. H., Fauci A. S. 1989; Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86:2365–2368 [View Article][PubMed]
    [Google Scholar]
  87. Gabriel R., Lombardo A., Arens A., Miller J. C., Genovese P., Kaeppel C., Nowrouzi A., Bartholomae C. C., Wang J. other authors 2011; An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29:816–823 [View Article][PubMed]
    [Google Scholar]
  88. Gandhi R. T., Zheng L., Bosch R. J., Chan E. S., Margolis D. M., Read S., Kallungal B., Palmer S., Medvik K. other authors 2010; The effect of Raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7:e1000321 [View Article][PubMed]
    [Google Scholar]
  89. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. 1986; The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215–219 [View Article][PubMed]
    [Google Scholar]
  90. Ghose R., Liou L. Y., Herrmann C. H., Rice A. P. 2001; Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4+ T lymphocytes by combination of cytokines. J Virol 75:11336–11343 [View Article][PubMed]
    [Google Scholar]
  91. Goldman J. P., Blundell M. P., Lopes L., Kinnon C., Di Santo J. P., Thrasher A. J. 1998; Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 103:335–342 [View Article][PubMed]
    [Google Scholar]
  92. González-Scarano F., Martín-García J. 2005; The neuropathogenesis of AIDS. Nat Rev Immunol 5:69–81 [View Article][PubMed]
    [Google Scholar]
  93. Greger I. H., Demarchi F., Giacca M., Proudfoot N. J. 1998; Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. Nucleic Acids Res 26:1294–1301 [View Article][PubMed]
    [Google Scholar]
  94. Gutiérrez C., Díaz L., Vallejo A., Hernández-Novoa B., Abad M., Madrid N., Dahl V., Rubio R., Moreno A. M. other authors 2011; Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS ONE 6:e27864 [View Article][PubMed]
    [Google Scholar]
  95. Haaland R. E., Yu W., Rice A. P. 2005; Identification of LKLF-regulated genes in quiescent CD4+ T lymphocytes. Mol Immunol 42:627–641 [View Article][PubMed]
    [Google Scholar]
  96. Halfon P., Giorgetti C., Khiri H., Pénaranda G., Terriou P., Porcu-Buisson G., Chabert-Orsini V. 2010; Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS ONE 5:e10569 [View Article][PubMed]
    [Google Scholar]
  97. Han Y., Lassen K., Monie D., Sedaghat A. R., Shimoji S., Liu X., Pierson T. C., Margolick J. B., Siliciano R. F., Siliciano J. D. 2004; Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 78:6122–6133 [View Article][PubMed]
    [Google Scholar]
  98. Han Y., Wind-Rotolo M., Yang H. C., Siliciano J. D., Siliciano R. F. 2007; Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 5:95–106 [View Article][PubMed]
    [Google Scholar]
  99. Han Y., Lin Y. B., An W., Xu J., Yang H. C., O’Connell K., Dordai D., Boeke J. D., Siliciano J. D., Siliciano R. F. 2008; Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4:134–146 [View Article][PubMed]
    [Google Scholar]
  100. Hatano H., Hayes T. L., Dahl V., Sinclair E., Lee T. H., Hoh R., Lampiris H., Hunt P. W., Palmer S. other authors 2011; A randomized, controlled trial of Raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 203:960–968 [View Article][PubMed]
    [Google Scholar]
  101. Hecht R., Stover J., Bollinger L., Muhib F., Case K., de Ferranti D. 2010; Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet 376:1254–1260 [View Article][PubMed]
    [Google Scholar]
  102. Hermankova M., Siliciano J. D., Zhou Y., Monie D., Chadwick K., Margolick J. B., Quinn T. C., Siliciano R. F. 2003; Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 77:7383–7392 [View Article][PubMed]
    [Google Scholar]
  103. Hesselton R. M., Greiner D. L., Mordes J. P., Rajan T. V., Sullivan J. L., Shultz L. D. 1995; High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis 172:974–982 [View Article][PubMed]
    [Google Scholar]
  104. Hirsch V. M., Fuerst T. R., Sutter G., Carroll M. W., Yang L. C., Goldstein S., Piatak M. Jr, Elkins W. R., Alvord W. G. other authors 1996; Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70:3741–3752[PubMed]
    [Google Scholar]
  105. Hirsch V. M., Lifson J. D., Kuah-Teh J. 2000; Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. In Advances in Pharmacology vol. 49 pp. 437–477 Academic Press; [View Article]
    [Google Scholar]
  106. Ho D. D., Rota T. R., Hirsch M. S. 1986; Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest 77:1712–1715 [View Article][PubMed]
    [Google Scholar]
  107. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. 1995; Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126 [View Article][PubMed]
    [Google Scholar]
  108. Holt N., Wang J., Kim K., Friedman G., Wang X., Taupin V., Crooks G. M., Kohn D. B., Gregory P. D. other authors 2010; Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28:839–847 [View Article][PubMed]
    [Google Scholar]
  109. Hosie M. J., Pajek D., Samman A., Willett B. J. 2011; Feline immunodeficiency virus (FIV) neutralization: a review. Viruses 3:1870–1890 [View Article][PubMed]
    [Google Scholar]
  110. Howard K. E., Reckling S. K., Egan E. A., Dean G. A. 2010; Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats. Retrovirology 7:2 [View Article][PubMed]
    [Google Scholar]
  111. Hütter G., Nowak D., Mossner M., Ganepola S., Müssig A., Allers K., Schneider T., Hofmann J., Kücherer C. other authors 2009; Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360:692–698 [View Article][PubMed]
    [Google Scholar]
  112. Joos B., Fischer M., Kuster H., Pillai S. K., Wong J. K., Böni J., Hirschel B., Weber R., Trkola A., Günthard H. F. Swiss HIV Cohort Study 2008; HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 105:16725–16730 [View Article][PubMed]
    [Google Scholar]
  113. Jordan A., Bisgrove D., Verdin E. 2003; HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22:1868–1877 [View Article][PubMed]
    [Google Scholar]
  114. Josefsson L., Eriksson S., Sinclair E., Ho T., Killian M., Epling L., Shao W., Lewis B., Bacchetti P. other authors 2012; Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 206:28–34 [View Article][PubMed]
    [Google Scholar]
  115. Joshi A., Vahlenkamp T. W., Garg H., Tompkins W. A. F., Tompkins M. B. 2004; Preferential replication of FIV in activated CD4+CD25+T cells independent of cellular proliferation. Virology 321:307–322 [View Article][PubMed]
    [Google Scholar]
  116. Joshi A., Garg H., Tompkins M. B., Tompkins W. A. 2005; Different thresholds of T cell activation regulate FIV infection of CD4+CD25+ and CD4+CD25- cells. Virology 335:212–221 [View Article][PubMed]
    [Google Scholar]
  117. June C., Pablo T., Stein D., Mitsuyasu R., Lalezari J., Wang S., Lee G., Levine B., Tang W. other authors 2012; Induction of acquired CCR5 deficiency with zinc finger nuclease-modified autologous CD4 T cells (SB-728-T) correlates with increases in CD4 count and effects on viral load in HIV-infected subjects. In 19th Conference on Retroviruses and Opportunistic Infections (CROI)
    [Google Scholar]
  118. Kauder S. E., Bosque A., Lindqvist A., Planelles V., Verdin E. 2009; Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5:e1000495 [View Article][PubMed]
    [Google Scholar]
  119. Kerr J. S., Galloway S., Lagrutta A., Armstrong M., Miller T., Richon V. M., Andrews P. A. 2010; Nonclinical safety assessment of the histone deacetylase inhibitor Vorinostat. Int J Toxicol 29:3–19 [View Article][PubMed]
    [Google Scholar]
  120. Kornfeld H., Cruikshank W. W., Pyle S. W., Berman J. S., Center D. M. 1988; Lymphocyte activation by HIV-1 envelope glycoprotein. Nature 335:445–448 [View Article][PubMed]
    [Google Scholar]
  121. Kraase M., Sloan R., Klein D., Logan N., McMonagle L., Biek R., Willett B. J., Hosie M. J. 2010; Feline immunodeficiency virus env gene evolution in experimentally infected cats. Vet Immunol Immunopathol 134:96–106 [View Article][PubMed]
    [Google Scholar]
  122. Kulkosky J., Culnan D. M., Roman J., Dornadula G., Schnell M., Boyd M. R., Pomerantz R. J. 2001; Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98:3006–3015 [View Article][PubMed]
    [Google Scholar]
  123. Kumar P., Ban H.-S., Kim S.-S., Wu H., Pearson T., Greiner D. L., Laouar A., Yao J., Haridas V. other authors 2008; T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134:577–586 [View Article][PubMed]
    [Google Scholar]
  124. Kwara A., Delong A., Rezk N., Hogan J., Burtwell H., Chapman S., Moreira C. C., Kurpewski J., Ingersoll J. other authors 2008; Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 46:719–725 [View Article][PubMed]
    [Google Scholar]
  125. Kwon H. S., Brent M. M., Getachew R., Jayakumar P., Chen L. F., Schnolzer M., McBurney M. W., Marmorstein R., Greene W. C., Ott M. 2008; Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3:158–167 [View Article][PubMed]
    [Google Scholar]
  126. Lassen K. G., Bailey J. R., Siliciano R. F. 2004; Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol 78:9105–9114 [View Article][PubMed]
    [Google Scholar]
  127. Lassen K. G., Ramyar K. X., Bailey J. R., Zhou Y., Siliciano R. F. 2006; Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2:e68 [View Article][PubMed]
    [Google Scholar]
  128. Launay O., Tod M., Tschöpe I., Si-Mohamed A., Bélarbi L., Charpentier C., Goujard C., Taburet A. M., Lortholary O. other authors 2011; Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther 16:843–852 [View Article][PubMed]
    [Google Scholar]
  129. Le Douce V., Herbein G., Rohr O., Schwartz C. 2010; Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 7:32 [View Article][PubMed]
    [Google Scholar]
  130. Levy Y., Lacabaratz C., Weiss L., Viard J. P., Goujard C., Lelièvre J. D., Boué F., Molina J. M., Rouzioux C. other authors 2009; Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 119:997–1007[PubMed]
    [Google Scholar]
  131. Levy Y., Sereti I., Tambussi G., Routy J. P., Lelievre J. D., Delfraissy J. F., Molina J. M., Fischl M., Goujard C. other authors 2012; Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 55:291–300 [View Article][PubMed]
    [Google Scholar]
  132. Lewin S. R., Evans V. A., Elliott J. H., Spire B., Chomont N. 2011; Finding a cure for HIV: will it ever be achievable?. J Int AIDS Soc 14:4 [View Article][PubMed]
    [Google Scholar]
  133. Li Z., Guo J., Wu Y., Zhou Q. 2013; The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41:277–287 [View Article][PubMed]
    [Google Scholar]
  134. Lusic M., Marcello A., Cereseto A., Giacca M. 2003; Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 22:6550–6561 [View Article][PubMed]
    [Google Scholar]
  135. Mansky L. M., Temin H. M. 1995; Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087–5094[PubMed]
    [Google Scholar]
  136. Marcello A. 2006; Latency: the hidden HIV-1 challenge. Retrovirology 3:7[PubMed] [CrossRef]
    [Google Scholar]
  137. Margolis L., Shattock R. 2006; Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved?. Nat Rev Microbiol 4:312–317[PubMed] [CrossRef]
    [Google Scholar]
  138. Marini A., Harper J. M., Romerio F. 2008; An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 181:7713–7720[PubMed] [CrossRef]
    [Google Scholar]
  139. Marsden M. D., Zack J. A. 2009; Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63:7–10 [View Article][PubMed]
    [Google Scholar]
  140. Mbonye U., Karn J. 2011; Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 9:554–567 [View Article][PubMed]
    [Google Scholar]
  141. McDonnel S. J., Sparger E. E., Luciw P. A., Murphy B. G. 2012; Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. Virus Res 170:174–179 [View Article][PubMed]
    [Google Scholar]
  142. McMahon D., Jones J., Wiegand A., Gange S. J., Kearney M., Palmer S., McNulty S., Metcalf J. A., Acosta E. other authors 2010; Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50:912–919 [View Article][PubMed]
    [Google Scholar]
  143. McNamara L. A., Collins K. L. 2011; Hematopoietic stem/precursor cells as HIV reservoirs. Curr Opin HIV AIDS 6:43–48 [View Article][PubMed]
    [Google Scholar]
  144. Middleton T., Lim H. B., Montgomery D., Rockway T., Tang H., Cheng X. H., Lu L. J., Mo H. M., Kohlbrenner W. E., Molla A. 2004; Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles. Antiviral Res 64:35–45 [View Article][PubMed]
    [Google Scholar]
  145. Mowat A. M., Viney J. L. 1997; The anatomical basis of intestinal immunity. Immunol Rev 156:145–166 [View Article][PubMed]
    [Google Scholar]
  146. Murphy B., Vapniarsky N., Hillman C., Castillo D., McDonnel S., Moore P., Luciw P. A., Sparger E. E. 2012; FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection. Retrovirology 9:12 [View Article][PubMed]
    [Google Scholar]
  147. Neal T. F., Holland H. K., Baum C. M., Villinger F., Ansari A. A., Saral R., Wingard J. R., Fleming W. H. 1995; CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 86:1749–1756[PubMed]
    [Google Scholar]
  148. Nicholson J. K. A., Cross G. D., Callaway C. S., McDougal J. S. 1986; In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J Immunol 137:323–329[PubMed]
    [Google Scholar]
  149. North T. W., Higgins J., Deere J. D., Hayes T. L., Villalobos A., Adamson L., Shacklett B. L., Schinazi R. F., Luciw P. A. 2010; Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84:2913–2922 [View Article][PubMed]
    [Google Scholar]
  150. Novotney C., English R. V., Housman J., Davidson M. G., Nasisse M. P., Jeng C. R., Davis W. C., Tompkins M. B. 1990; Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus. AIDS 4:1213–1218 [View Article][PubMed]
    [Google Scholar]
  151. O’Brien S. J., Moore J. P. 2000; The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 177:99–111 [View Article][PubMed]
    [Google Scholar]
  152. O’Doherty U., Swiggard W. J., Malim M. H. 2000; Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74:10074–10080 [View Article][PubMed]
    [Google Scholar]
  153. Ostrowski M. A., Chun T. W., Justement S. J., Motola I., Spinelli M. A., Adelsberger J., Ehler L. A., Mizell S. B., Hallahan C. W., Fauci A. S. 1999; Both memory and CD45RA+/CD62L+ naive CD4+ T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 73:6430–6435[PubMed]
    [Google Scholar]
  154. Oswald-Richter K., Grill S. M., Leelawong M., Unutmaz D. 2004; HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur J Immunol 34:1705–1714 [View Article][PubMed]
    [Google Scholar]
  155. Pace M. J., Agosto L., Graf E. H., O’Doherty U. 2011; HIV reservoirs and latency models. Virology 411:344–354 [View Article][PubMed]
    [Google Scholar]
  156. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G. J., Brun S. C., Kempf D. J., Mellors J. W., Coffin J. M., King M. S. 2008; Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105:3879–3884 [View Article][PubMed]
    [Google Scholar]
  157. Palmer S., Josefsson L., Coffin J. M. 2011; HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 270:550–560 [View Article][PubMed]
    [Google Scholar]
  158. Parada C. A., Roeder R. G. 1996; Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384:375–378 [View Article][PubMed]
    [Google Scholar]
  159. Pattanayak V., Ramirez C. L., Joung J. K., Liu D. R. 2011; Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8:765–770 [View Article][PubMed]
    [Google Scholar]
  160. Pedersen N. C., Ho E. W., Brown M. L., Yamamoto J. K. 1987; Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235:790–793 [View Article][PubMed]
    [Google Scholar]
  161. Peer D., Karp J. M., Hong S., Farokhzad O. C., Margalit R., Langer R. 2007; Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760 [View Article][PubMed]
    [Google Scholar]
  162. Perez E. E., Wang J., Miller J. C., Jouvenot Y., Kim K. A., Liu O., Wang N., Lee G., Bartsevich V. V. other authors 2008; Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26:808–816 [View Article][PubMed]
    [Google Scholar]
  163. Pérez-Martínez D., Tanaka T., Rabbitts T. H. 2010; Intracellular antibodies and cancer: new technologies offer therapeutic opportunities. Bioessays 32:589–598 [View Article][PubMed]
    [Google Scholar]
  164. Pierson T., Hoffman T. L., Blankson J., Finzi D., Chadwick K., Margolick J. B., Buck C., Siliciano J. D., Doms R. W., Siliciano R. F. 2000; Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 74:7824–7833 [View Article][PubMed]
    [Google Scholar]
  165. Pierson T. C., Zhou Y., Kieffer T. L., Ruff C. T., Buck C., Siliciano R. F. 2002; Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 76:8518–8531 [View Article][PubMed]
    [Google Scholar]
  166. Prins J. M., Jurriaans S., van Praag R. M., Blaak H., van Rij R., Schellekens P. T., ten Berge I. J., Yong S. L., Fox C. H. other authors 1999; Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405–2410 [View Article][PubMed]
    [Google Scholar]
  167. Ramratnam B., Mittler J. E., Zhang L., Boden D., Hurley A., Fang F., Macken C. A., Perelson A. S., Markowitz M., Ho D. D. 2000; The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6:82–85 [View Article][PubMed]
    [Google Scholar]
  168. Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J. S., Quivy V., Vanhulle C., Lamine A., Vaira D. other authors 2009; Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4:e6093 [View Article][PubMed]
    [Google Scholar]
  169. Richman D. D., Margolis D. M., Delaney M., Greene W. C., Hazuda D., Pomerantz R. J. 2009; The challenge of finding a cure for HIV infection. Science 323:1304–1307 [View Article][PubMed]
    [Google Scholar]
  170. Roesch F., Meziane O., Kula A., Nisole S., Porrot F., Anderson I., Mammano F., Fassati A., Marcello A. other authors 2012; Hyperthermia stimulates HIV-1 replication. PLoS Pathog 8:e1002792 [View Article][PubMed]
    [Google Scholar]
  171. Rossi M. I., Medina K. L., Garrett K., Kolar G., Comp P. C., Shultz L. D., Capra J. D., Wilson P., Schipul A., Kincade P. W. 2001; Relatively normal human lymphopoiesis but rapid turnover of newly formed B cells in transplanted nonobese diabetic/SCID mice. J Immunol 167:3033–3042[PubMed] [CrossRef]
    [Google Scholar]
  172. Ruff C. T., Ray S. C., Kwon P., Zinn R., Pendleton A., Hutton N., Ashworth R., Gange S., Quinn T. C. other authors 2002; Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 76:9481–9492 [View Article][PubMed]
    [Google Scholar]
  173. Rullas J., Bermejo M., García-Pérez J., Beltán M., González N., Hezareh M., Brown S. J., Alcamí J. 2004; Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther 9:545–554[PubMed]
    [Google Scholar]
  174. Sahu G. K., Lee K., Ji J. X., Braciale V., Baron S., Cloyd M. W. 2006; A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 355:127–137 [View Article][PubMed]
    [Google Scholar]
  175. Sahu G. K., Paar D., Frost S. D. W., Smith M. M., Weaver S., Cloyd M. W. 2009; Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 81:9–15 [View Article][PubMed]
    [Google Scholar]
  176. Saleh S., Solomon A., Wightman F., Xhilaga M., Cameron P. U., Lewin S. R. 2007; CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110:4161–4164 [View Article][PubMed]
    [Google Scholar]
  177. Saleh S., Wightman F., Ramanayake S., Alexander M., Kumar N., Khoury G., Pereira C., Purcell D., Cameron P. U., Lewin S. R. 2011; Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology 8:80 [View Article][PubMed]
    [Google Scholar]
  178. Schnittman S. M., Psallidopoulos M. C., Lane H. C., Thompson L., Baseler M., Massari F., Fox C. H., Salzman N. P., Fauci A. S. 1989; The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 245:305–308 [View Article][PubMed]
    [Google Scholar]
  179. Schröder A. R., Shinn P., Chen H., Berry C., Ecker J. R., Bushman F. 2002; HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521–529 [View Article][PubMed]
    [Google Scholar]
  180. Scripture-Adams D. D., Brooks D. G., Korin Y. D., Zack J. A. 2002; Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 76:13077–13082 [View Article][PubMed]
    [Google Scholar]
  181. Shan L., Deng K., Shroff N. S., Durand C. M., Rabi S. A., Yang H. C., Zhang H., Margolick J. B., Blankson J. N., Siliciano R. F. 2012; Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491–501 [View Article][PubMed]
    [Google Scholar]
  182. Shen A. D., Zink M. C., Mankowski J. L., Chadwick K., Margolick J. B., Carruth L. M., Li M., Clements J. E., Siliciano R. F. 2003; Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 77:4938–4949 [View Article][PubMed]
    [Google Scholar]
  183. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E. L., Haining H., Akashi H., Takeuchi Y., Hosie M. J., Willett B. J. 2004; Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303:1192–1195 [View Article][PubMed]
    [Google Scholar]
  184. Siliciano, R. F. & Greene, W. C. (2011 HIV Latency. Cold Spring Harbor Perspectives in Medicine 1
  185. Siliciano J. D., Siliciano R. F. 2010; Biomarkers of HIV replication. Curr Opin HIV AIDS 5:491–497 [View Article][PubMed]
    [Google Scholar]
  186. Siliciano J. D., Kajdas J., Finzi D., Quinn T. C., Chadwick K., Margolick J. B., Kovacs C., Gange S. J., Siliciano R. F. 2003; Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727–728 [View Article][PubMed]
    [Google Scholar]
  187. Sloan R. D., Wainberg M. A. 2011; The role of unintegrated DNA in HIV infection. Retrovirology 8:52 [View Article][PubMed]
    [Google Scholar]
  188. Stanley S. K., Kessler S. W., Justement J. S., Schnittman S. M., Greenhouse J. J., Brown C. C., Musongela L., Musey K., Kapita B., Fauci A. S. 1992; CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 149:689–697[PubMed]
    [Google Scholar]
  189. Stevenson M., Stanwick T. L., Dempsey M. P., Lamonica C. A. 1990; HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 9:1551–1560[PubMed]
    [Google Scholar]
  190. Svarovskaia E. S., Barr R., Zhang X. C., Pais G. C. G., Marchand C., Pommier Y., Burke T. R. Jr, Pathak V. K. 2004; Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 78:3210–3222 [View Article][PubMed]
    [Google Scholar]
  191. Swan C. H., Bühler B., Tschan M. P., Barbas C. F., Torbett B. E. 2006; T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13:1480–1492 [View Article][PubMed]
    [Google Scholar]
  192. Tobin N. H., Learn G. H., Holte S. E., Wang Y., Melvin A. J., McKernan J. L., Pawluk D. M., Mohan K. M., Lewis P. F. other authors 2005; Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 79:9625–9634 [View Article][PubMed]
    [Google Scholar]
  193. Tompkins M. B., Tompkins W. A. 2008; Lentivirus-induced immune dysregulation. Vet Immunol Immunopathol 123:45–55 [View Article][PubMed]
    [Google Scholar]
  194. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J. C., Lanzavecchia A., Manz M. G. 2004; Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104–107 [View Article][PubMed]
    [Google Scholar]
  195. Trautmann L., Janbazian L., Chomont N., Said E. A., Gimmig S., Bessette B., Boulassel M.-R., Delwart E., Sepulveda H. other authors 2006; Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12:1198–1202 [View Article][PubMed]
    [Google Scholar]
  196. Tyagi M., Pearson R. J., Karn J. 2010; Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 84:6425–6437 [View Article][PubMed]
    [Google Scholar]
  197. Tzachanis D., Lafuente E. M., Li L., Boussiotis V. A. 2004; Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk Lymphoma 45:1959–1967 [View Article][PubMed]
    [Google Scholar]
  198. Urnov F. D., Miller J. C., Lee Y.-L., Beausejour C. M., Rock J. M., Augustus S., Jamieson A. C., Porteus M. H., Gregory P. D., Holmes M. C. 2005; Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435:646–651 [View Article][PubMed]
    [Google Scholar]
  199. Van Duyne R., Pedati C., Guendel I., Carpio L., Kehn-Hall K., Saifuddin M., Kashanchi F. 2009; The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 6:76 [View Article][PubMed]
    [Google Scholar]
  200. van Grevenynghe J., Procopio F. A., He Z., Chomont N., Riou C., Zhang Y., Gimmig S., Boucher G., Wilkinson P. other authors 2008; Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection. Nat Med 14:266–274 [View Article][PubMed]
    [Google Scholar]
  201. van Leeuwen E. M. M., Sprent J., Surh C. D. 2009; Generation and maintenance of memory CD4+ T cells. Curr Opin Immunol 21:167–172 [View Article][PubMed]
    [Google Scholar]
  202. Van Lint C., Emiliani S., Ott M., Verdin E. 1996; Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112–1120[PubMed]
    [Google Scholar]
  203. Vatakis D. N., Bristol G., Wilkinson T. A., Chow S. A., Zack J. A. 2007; Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol 81:3574–3582 [View Article][PubMed]
    [Google Scholar]
  204. Vatakis D. N., Kim S., Kim N., Chow S. A., Zack J. A. 2009; Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol 83:6222–6233 [View Article][PubMed]
    [Google Scholar]
  205. Vatakis D. N., Nixon C. C., Zack J. A. 2010; Quiescent T cells and HIV: an unresolved relationship. Immunol Res 48:110–121 [View Article][PubMed]
    [Google Scholar]
  206. Verdin E., Paras P. Jr, Van Lint C. 1993; Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249–3259[PubMed]
    [Google Scholar]
  207. Volberding P. A., Deeks S. G. 2010; Antiretroviral therapy and management of HIV infection. Lancet 376:49–62 [View Article][PubMed]
    [Google Scholar]
  208. Wang F. X., Xu Y., Sullivan J., Souder E., Argyris E. G., Acheampong E. A., Fisher J., Sierra M., Thomson M. M. other authors 2005; IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 115:128–137[PubMed] [CrossRef]
    [Google Scholar]
  209. Weissman D., Rabin R. L., Arthos J., Rubbert A., Dybul M., Swofford R., Venkatesan S., Farber J. M., Fauci A. S. 1997; Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389:981–985 [View Article][PubMed]
    [Google Scholar]
  210. Wightman F., Solomon A., Khoury G., Green J. A., Gray L., Gorry P. R., Ho Y. S., Saksena N. K., Hoy J. other authors 2010; Both CD31+ and CD31⁻ naive CD4+ T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 202:1738–1748 [View Article][PubMed]
    [Google Scholar]
  211. Wightman F., Ellenberg P., Churchill M., Lewin S. R. 2012; HDAC inhibitors in HIV. Immunol Cell Biol 90:47–54 [View Article][PubMed]
    [Google Scholar]
  212. Wilen C. B., Wang J., Tilton J. C., Miller J. C., Kim K. A., Rebar E. J., Sherrill-Mix S. A., Patro S. C., Secreto A. J. other authors 2011; Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 7:e1002020 [View Article][PubMed]
    [Google Scholar]
  213. Willett B. J., Picard L., Hosie M. J., Turner J. D., Adema K., Clapham P. R. 1997; Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 71:6407–6415[PubMed]
    [Google Scholar]
  214. Williams S. A., Greene W. C. 2007; Regulation of HIV-1 latency by T-cell activation. Cytokine 39:63–74 [View Article][PubMed]
    [Google Scholar]
  215. Williams S. A., Kwon H., Chen L. F., Greene W. C. 2007; Sustained induction of NF-κB is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 81:6043–6056 [View Article][PubMed]
    [Google Scholar]
  216. Wolschendorf F., Duverger A., Jones J., Wagner F. H., Huff J., Benjamin W. H., Saag M. S., Niederweis M., Kutsch O. 2010; Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 84:8712–8720 [View Article][PubMed]
    [Google Scholar]
  217. Wu Y. T., Yoder A. 2009; Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 5:e1000520 [View Article][PubMed]
    [Google Scholar]
  218. Wu L. J., Paxton W. A., Kassam N., Ruffing N., Rottman J. B., Sullivan N., Choe H., Sodroski J., Newman W. other authors 1997; CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 185:1681–1692 [View Article][PubMed]
    [Google Scholar]
  219. Xing S., Bullen C. K., Shroff N. S., Shan L., Yang H. C., Manucci J. L., Bhat S., Zhang H., Margolick J. B. other authors 2011; Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85:6060–6064 [View Article][PubMed]
    [Google Scholar]
  220. Xing S. F., Bhat S., Shroff N. S., Zhang H., Lopez J. A., Margolick J. B., Liu J. O., Siliciano R. F. 2012; Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 67:398–403 [View Article][PubMed]
    [Google Scholar]
  221. Yamamoto J. K., Sparger E., Ho E. W., Andersen P. R., O’Connor T. P., Mandell C. P., Lowenstine L., Munn R., Pedersen N. C. 1988; Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 49:1246–1258[PubMed]
    [Google Scholar]
  222. Yamamoto J. K., Hansen H., Ho E. W., Morishita T. Y., Okuda T., Sawa T. R., Nakamura R. M., Pedersen N. C. 1989; Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc 194:213–220[PubMed]
    [Google Scholar]
  223. Yang H. C. 2011; Primary cell models of HIV latency. Curr Opin HIV AIDS 6:62–67 [View Article][PubMed]
    [Google Scholar]
  224. Yang H. C., Xing S. F., Shan L., O’Connell K., Dinoso J., Shen A. D., Zhou Y., Shrum C. K., Han Y. F. other authors 2009; Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 119:3473–3486[PubMed]
    [Google Scholar]
  225. Yeung F., Hoberg J. E., Ramsey C. S., Keller M. D., Jones D. R., Frye R. A., Mayo M. W. 2004; Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369–2380 [View Article][PubMed]
    [Google Scholar]
  226. Ylisastigui L., Archin N. M., Lehrman G., Bosch R. J., Margolis D. M. 2004; Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18:1101–1108 [View Article][PubMed]
    [Google Scholar]
  227. Yoder A., Yu D. Y., Dong L., Iyer S. R., Xu X. H., Kelly J., Liu J., Wang W. F., Vorster P. J. other authors 2008; HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134:782–792 [View Article][PubMed]
    [Google Scholar]
  228. Yuan J., Wang J., Crain K., Fearns C., Kim K. A., Hua K. L., Gregory P. D., Holmes M. C., Torbett B. E. 2012; Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4+ T cell resistance and enrichment. Mol Ther 20:849–859 [View Article][PubMed]
    [Google Scholar]
  229. Yukl S. A., Shergill A. K., McQuaid K., Gianella S., Lampiris H., Hare C. B., Pandori M., Sinclair E., Günthard H. F. other authors 2010; Effect of Raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24:2451–2460 [View Article][PubMed]
    [Google Scholar]
  230. Yusuf I., Fruman D. A. 2003; Regulation of quiescence in lymphocytes. Trends Immunol 24:380–386 [View Article][PubMed]
    [Google Scholar]
  231. Zagury D., Bernard J., Leonard R., Cheynier R., Feldman M., Sarin P. S., Gallo R. C. 1986; Long-term cultures of HTLV-III–infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 231:850–853 [View Article][PubMed]
    [Google Scholar]
  232. Zhou Y., Zhang H., Siliciano J. D., Siliciano R. F. 2005; Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79:2199–2210 [View Article][PubMed]
    [Google Scholar]
  233. Zhu T., Mo H., Wang N., Nam D. S., Cao Y., Koup R. A., Ho D. D. 1993; Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179–1181 [View Article][PubMed]
    [Google Scholar]
  234. Zhu J., Gaiha G. D., John S. P., Pertel T., Chin C. R., Gao G., Qu H., Walker B. D., Elledge S. J., Brass A. L. 2012; Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2:807–816 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.049296-0
Loading
/content/journal/jgv/10.1099/vir.0.049296-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error